RARX Description — Ra Pharmaceuticals Inc
Ra Pharmaceuticals is a clinical-stage biopharmaceutical company using its proprietary peptide chemistry platform to develop therapeutics for the treatment of diseases that are caused by excessive or uncontrolled activation of the complement system, a primary component of the immune system. Co. is developing its primary product candidate, zilucoplan, a synthetic, macrocyclic peptide C5 inhibitor, formulated for self-administered, subcutaneous injection, which is an injection into the tissue under the skin, for the treatment of various complement-mediated diseases, including generalized myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and other complement-mediated disorders.